O

Oculis Holding AG
NASDAQ:OCS

Watchlist Manager
Oculis Holding AG
NASDAQ:OCS
Watchlist
Price: 19.84 USD -3.08% Market Closed
Market Cap: 1.1B USD

Relative Value

There is not enough data to reliably calculate the relative value of OCS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OCS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
Forward
951.7
vs History
vs Industry
Median 3Y
-8
Median 5Y
-9.2
Industry
21.6
Forward
-9
vs History
vs Industry
Median 3Y
-12.2
Median 5Y
-14.5
Industry
16.5
vs History
vs Industry
Median 3Y
-11.3
Median 5Y
-14
Industry
22.5
vs History
7
vs Industry
6
Median 3Y
4.2
Median 5Y
3.4
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
Forward
903.8
vs History
vs Industry
Median 3Y
-16.2
Median 5Y
-19.9
Industry
5.5
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-12.4
Industry
13
Forward
-9.9
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-12.4
Industry
16.6
Forward
-10.5
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-15.6
Industry
15.8
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-14.3
Industry
19.1
vs History
22
vs Industry
10
Median 3Y
6.1
Median 5Y
4.9
Industry
1.9

Multiples Across Competitors

OCS Competitors Multiples
Oculis Holding AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Oculis Holding AG
NASDAQ:OCS
1.1B USD 0 -8.5 -10.8 -10.7
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 16.8 54.2 36.3 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
503.6B USD 5.5 20 16.4 21.3
CH
Roche Holding AG
SIX:ROG
251.4B CHF 4.1 26.7 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
211.3B GBP 4.9 30.2 108.7 159.1
CH
Novartis AG
SIX:NOVN
206.9B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
244.4B USD 3.8 12.8 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.1 10.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
145.2B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
CH
O
Oculis Holding AG
NASDAQ:OCS
Average P/E: 23.7
Negative Multiple: -8.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.7
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
O
Oculis Holding AG
NASDAQ:OCS
Average EV/EBITDA: 438.8
Negative Multiple: -10.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
O
Oculis Holding AG
NASDAQ:OCS
Average EV/EBIT: 1 881.2
Negative Multiple: -10.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
1%
10.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3